


How similar is this cluster to the other clusters?




Genes in the cluster along with the pathways as annotated by experts

Treatment	Expert Annotation	
	Pathway	Regulation Type
CDKN1A.WT	Canonical Cell Cycle	Inhibitor
MAP3K5.WT	Canonical MAPK	Activator
MAP2K4.WT.1	Canonical MAPK	Activator
MAP2K3.WT	Canonical MAPK	Activator
KRAS.G12V	RTK	Activator
HRAS.G12V	RTK	Activator


Top 5 genes negatively correlated to the cluster

Treatment	Expert Annotation		Mean Correlation	Standard Deviation
	Pathway	Regulation Type		
E2F1.WT	Canonical Cell Cycle	Activator	-0.59	0.09
CCND1.WT.2	Canonical Cell Cycle	Activator	-0.58	0.08
CDK2.WT.1	Canonical Cell Cycle	Activator	-0.49	0.11
DDIT4.WT	Canonical TOR	Inhibitor	-0.49	0.07
PER1.WT.2	Circadian Rhythm	Activator	-0.49	0.09

What groups of morphological features are distinguishing in the cluster relative to the untreated samples? (maximum of absolute m-score for the features belonging to the same category; m-score defined as median of a feature z-score across genes in the cluster) Black means no feature is available in the category



Which individual morphological features are distinguishing in the cluster relative to the untreated samples? Blue/Red means the feature has a positive/negative z-score. Size is proportional to the z-score value.



How strongly are genes within the cluster correlated?




























Plate : 41744 - Genes in the Cluster (Channels are sorted based on their dominance in the grid plot)



Compound IDs and common names (where available); blue/red colored box means the matching compound is positively/negatively correlated with the cluster	Chemical structure	Mean pairwise replicates correlation of the compound signature (95th DMSO replicate correlation is 0.52)	Mean standard deviation correlation between compound and each gene in cluster; Tables contain data for individual genes	Mean compound rank when scored against genes in cluster using L1000 profiling $\pm$ standard deviation; Tables contain data for individual genes	How similar is the compound signature to the gene clusters in this experiment? (Yellow and red lines correspond to top/bottom 1st and 5th percentile DMSO correlation to all the genes)	Common distinguishing feature categories in the compound and genes in the cluster relative to the untreated samples	Distinguishing individual features for the compound relative to untreated samples. Black means a mismatch; i.e. active (= high z-score in magnitude) in the compound, and either inactive (= small z-score in magnitude) or oppositely active in the gene cluster	Number of PubChem assays in which the compound was tested; assays in which the compound was active are itemized														
BRD-A81850691-001-05-0 F1734-0091 ACINJT6B MLS000697333 HMS2580B04 SMR000238009 ST50110788 PubChem CID : 4902407		0.95 (in 4 replicates)	<table><tr><th>Treatment</th><th>Score</th></tr><tr><td>CHKIN.WT</td><td>0.047</td></tr><tr><td>HKARI.G2V</td><td>0.075</td></tr><tr><td>HKARI.G2V</td><td>0.038</td></tr><tr><td>MAPK1.WT</td><td>0.066</td></tr><tr><td>MAPK1.WT</td><td>0.071</td></tr><tr><td>MAPK1.WT</td><td>0.073</td></tr></table>	Treatment	Score	CHKIN.WT	0.047	HKARI.G2V	0.075	HKARI.G2V	0.038	MAPK1.WT	0.066	MAPK1.WT	0.071	MAPK1.WT	0.073	NA				Total number of assays tested in: 639. Active in the following assays: <ul style="list-style-type: none"><li>Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex (AID 2216)</li><li>High Content Assay for Compounds that inhibit the Assembly of the Perinuclear Compartment (AID 2417)</li><li>Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1) (AID 652257)</li></ul>
Treatment	Score																					
CHKIN.WT	0.047																					
HKARI.G2V	0.075																					
HKARI.G2V	0.038																					
MAPK1.WT	0.066																					
MAPK1.WT	0.071																					
MAPK1.WT	0.073																					
BRD-K40926874-001-06-3 T6051781 ACIOBTHD MLS000516321 ZINC12727563 SMR000372882 PubChem CID : 6902822		0.90 (in 3 replicates)	<table><tr><th>Treatment</th><th>Score</th></tr><tr><td>CHKIN.WT</td><td>0.080</td></tr><tr><td>HKARI.G2V</td><td>0.076</td></tr><tr><td>HKARI.G2V</td><td>0.053</td></tr><tr><td>MAPK1.WT</td><td>0.064</td></tr><tr><td>MAPK1.WT</td><td>0.066</td></tr><tr><td>MAPK1.WT</td><td>0.071</td></tr></table>	Treatment	Score	CHKIN.WT	0.080	HKARI.G2V	0.076	HKARI.G2V	0.053	MAPK1.WT	0.064	MAPK1.WT	0.066	MAPK1.WT	0.071	NA				Total number of assays tested in: 636. Active in the following assays: <ul style="list-style-type: none"><li>qHTS Assay for Inhibitors of Aldelyde Dehydrogenase 1 (ALDH1A1) (AID 1030)</li><li>qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase) (AID 1490)</li><li>VP16 countercreen qHTS for inhibitors of ROR gamma transcriptional activity (AID 2546)</li><li>qHTS for inhibitors of ROR gamma transcriptional activity (AID 2551)</li><li>uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay (AID 463190)</li><li>uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay (AID 463212)</li><li>Single concentration confirmation of small molecule inhibitors of tim0-1 yeast via a luminescent assay (AID 463213)</li><li>Single concentration confirmation of small molecule inhibitors of tim23-1 yeast via a luminescent assay (AID 463218)</li><li>HTS-Luminescent assay for inhibitors of AIR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02-Inhibitor.SinglePoint HTS (AID 485317)</li><li>qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a (AID 504332)</li></ul>
Treatment	Score																					
CHKIN.WT	0.080																					
HKARI.G2V	0.076																					
HKARI.G2V	0.053																					
MAPK1.WT	0.064																					
MAPK1.WT	0.066																					
MAPK1.WT	0.071																					






BRD-K90238417-001-07-4  
SMR000043477  
MLS000083198  
STK592720  
AC1NTW47  
MLS002584074  
BDBM67730  
HMS2424N11  
ZINC9111495  
ZINC09111495  
PubChem CID : 5389598



0.91 (in 4 replicates)


Treatment	Score
CDKN1A.WT	0.81
HRAS.G12V	0.74
KRAS.G12V	0.48
MAP2K3.WT	0.65
MAP2K4.WT.1	0.67
MAP3K5.WT	0.71

Treatment	Score
CDKN1A.WT	0.136
HRAS.G12V	0.758
KRAS.G12V	0.696
MAP2K3.WT	0.778
MAP2K4.WT.1	0.723
MAP3K5.WT	0.054






775. Total number of assays tested in: 775. Active in the following assays:
- MLPCN Streptokinase Expression Inhibition (AID 1662)
- qFRET-based primary biochemical high throughput screening assay to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP), (AID 1822)
- Luminescence Microorganism-Based Dose Confirmation HTS to Identify Compounds Cytotoxic to SK1-IGAS Group A Streptococcus (AID 1900)
- Luminescence Microorganism-Based Dose Confirmation HTS to Identify Inhibitors of Streptokinase Promoter Activity (AID 1902)
- Luminescence Microorganism-Based Dose Response HTS to Identify Compounds Cytotoxic to Streptococcus (AID 1915)
- Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of the Ras-converting Enzyme (AID 2563)
- HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress (AID 2732)
- CHOP dose-response: primary assay (AID 504322)
- CHOP Confirmary Screen (AID 504437)
- qHTS for Inhibitors of binding or entry into cells for Lassa Virus (AID 540256)
- wHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay (AID 602419)
- Counter-screen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease (AID 621483)
- Single concentration confirmation of wHTS inhibitor hits of the mitochondrial permeability transition pore via a fluorescent based assay (AID 624504)
- qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1); qHTS in cells in absence of CPT (AID 686978)
- qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1); qHTS in cells in presence of CPT (AID 686979)

BRD-K99043334-001-05-3  
T5820256  
SMR000028676  
MLS000093046  
AC1MMDH8  
MLS000863462  
HMS2432G12  
ZINC57388152  
ST51073581  
PubChem CID : 3237033



0.91 (in 3 replicates)


Treatment	Score
CDKN1A.WT	0.80
HRAS.G12V	0.73
KRAS.G12V	0.48
MAP2K3.WT	0.64
MAP2K4.WT.1	0.68
MAP3K5.WT	0.71

NA

Total number of assays tested in: 773. Active in the following assays:




- Cytochrome panel assay with activity outcomes (AID 1851)
- Primary qHTS for delayed death inhibitors of the malarial parasite plasmodium, 96 hour incubation (AID 504834)

BRD-K78412459-001-07-0  
MLS000095975  
SMR000031523  
AC1MMEHN  
BDBM64930  
HMS1510I13  
HMS2441M20  
PubChem CID : 3237493



0.89 (in 3 replicates)


Treatment	Score
CDKN1A.WT	0.78
HRAS.G12V	0.74
KRAS.G12V	0.48
MAP2K3.WT	0.65
MAP2K4.WT.1	0.66
MAP3K5.WT	0.72

NA

Total number of assays tested in: 789. Active in the following assays:




- CYP2C9 Assay (ADD 777)
- HCS for Compounds that Up-Regulate Interleukin Promoter Activity in MING Cells (ADD 1625)
- qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP) (ADD 1688)
- Fluorescence Cell-Based Primary HTS of Calibans growth in the presence of Fluconazole and compound (ADD 1979)
- Fluorescence Cell-Based Secondary Assay to Identify Inhibitors of Resistant *C. albicans* Growth in the Presence of Fluconazole (ADD 2125)
- Fluorescence Cell-Based Retest of *C. albicans* Growth in the Presence of Fluconazole (ADD 2467)
- Primary qHTS for delayed death inhibitors of the malarial parasite plasmod, 96 hour incubation (ADD 504834)

BRD-K74121099-001-05-1  
MLS000089134  
SMR000072827  
ACILPNXS  
Ambcb7481403  
MLS002541642  
BDBM56185  
HMS2451A15  
ZINC1136310  
ZINC01136310  
VU0177852-6  
PubChem CID : 1310230



0.88 (in 3 replicates)


Treatment	Score
CDKN1A.WT	0.79
HRAS.G12V	0.74
KRAS.G12V	0.49
MAP2K3.WT	0.63
MAP2K4.WT.1	0.65
MAP3K5.WT	0.69

NA

Total number of assays tested in: 786. Active in the following assays:




- Fluorescent HTS Cytotoxicity/Cytoviability assay (HPDE-C7 cells) (AID 430)
- Kallikrein 5 1536 HTS (AID 873)
- qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay (AID 995)
- Image-based Screening Assay for Inhibitors of Phagocytosis (AID 1029)
- Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5). (AID 1987)
- Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT) (AID 488975)
- Confirmatory screen for compounds that inhibit the Choline Transporter (CHT) (AID 493221)
- Dose responses of compounds that inhibit the Choline Transporter (CHT) - 5 point CIRC (AID 504840)
- TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R); antagonists of MC4R (AID 540295)
- Dose responses of compounds that inhibit the Choline Transporter (CHT) - 10 point CIRC (AID 558401)
- Countercreens for biased ligands (antagonists) of the melanocortin 4 receptor (MC4R): TRFRET-based cell-based high throughput assay to identify nonselective inhibitors of cAMP signaling (AID 602193)
- TRFRET-based cell-based high throughput assay to identify nonselective inhibitors of cAMP signaling (AID 602193)
- qHTS Assay for Inhibitors of Hepatitis C Virus (HCV) (AID 615820)
- qHTS for Inhibitors of Inflammation Signaling: IL-1beta Alpha/ISA Primary Screen (AID 743279)
- Confirmed inhibitors of the Choline Transporter (CHT) (AID 1053196)

BRD-A50921700-001-05-5  
ST50843211  
AC1MG1XY  
MLS001035763  
HMS2980J20  
STK436533  
SMR000666319  
PubChem CID : 2954221



NA (in 1 replicates)

















Treatment	Score
CDKN1A.WT	0.73
HRAS.G12V	0.73
KRAS.G12V	0.49
MAP2K3.WT	0.64
MAP2K4.WT.1	0.63
MAP3K5.WT	0.72

NA

Total number of assays tested in: 491. Active in the following assays:


- uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase (AID 2524)
- qHTS for inhibitors of ROR gamma transcriptional activity (AID 2551)



<div>BRD-A77566727-001-05-6</div> <div>SMR000048526</div> <div>AC1LDHJDJ</div> <div>MLS000084442</div> <div>MLS002584781</div> <div>HMS2405B07</div> <div>STK788882</div> <div>ST50129984</div> <div>PubChem CID : 667105</div>	<div></div>	<div>0.87 (in 4 replicates)</div>	<div><div>0.65 ± 0.11</div><table><tr><th>Treatment</th><th>Score</th></tr><tr><td>CURNTA.WT</td><td>0.77</td></tr><tr><td>HRAS.G12V</td><td>0.71</td></tr><tr><td>KRAS.G12V</td><td>0.45</td></tr><tr><td>MAP3K1.WT</td><td>0.61</td></tr><tr><td>MAP3K1.WT.1</td><td>0.61</td></tr><tr><td>MAP3K1.WT</td><td>0.68</td></tr></table></div>	Treatment	Score	CURNTA.WT	0.77	HRAS.G12V	0.71	KRAS.G12V	0.45	MAP3K1.WT	0.61	MAP3K1.WT.1	0.61	MAP3K1.WT	0.68	<div>NA</div>	<div></div>	<div></div>	<div></div>	<div>Total number of assays tested in: 775. Active in the following assays:</div> <div><ul style="list-style-type: none"><li>• CYP2C9 Assay (AID 777)</li><li>• qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1) (AID 1030)</li><li>• uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (eIF4H) (AID 2012)</li><li>• uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP) (AID 2014)</li><li>• Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide. (AID 2057)</li><li>• Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL). (AID 2129)</li><li>• Primary qHTS for delayed death inhibitors of the malarial parasite plasid, 96 hour incubation (AID 504834)</li><li>• Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHO-K1 cell line (AID 602250)</li><li>• Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, aldehyde domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5) with perilipin-5 (MLDP; PLIN5) (AID 602281)</li><li>• Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4) (AID 624126)</li><li>• Counterscreen for inhibitors of the interaction of the lipase co-activator protein, aldehyde domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5): Luminescence-based biochemical high throughput assay to identify inhibitors of Hepatocyte nuclear factor 4 (HNF4) dimerization (AID 651674)</li></ul></div>
Treatment	Score																					
CURNTA.WT	0.77																					
HRAS.G12V	0.71																					
KRAS.G12V	0.45																					
MAP3K1.WT	0.61																					
MAP3K1.WT.1	0.61																					
MAP3K1.WT	0.68																					
<div>BRD-K38340366-001-10-8</div> <div>MLS001207806</div> <div>MLS003876590</div> <div>SMR000517221</div> <div>ST50155362</div> <div>ZINC04974015</div> <div>AC1NY521</div> <div>BDBM67642</div> <div>HMS2817L13</div> <div>ML280</div> <div>ZINC4974015</div> <div>BAS 01966230</div> <div>PubChem CID : 5765514</div>	<div></div>	<div>0.85 (in 4 replicates)</div>	<div><div>0.65 ± 0.10</div><table><tr><th>Treatment</th><th>Score</th></tr><tr><td>CURNTA.WT</td><td>0.77</td></tr><tr><td>HRAS.G12V</td><td>0.71</td></tr><tr><td>KRAS.G12V</td><td>0.48</td></tr><tr><td>MAP3K1.WT</td><td>0.62</td></tr><tr><td>MAP3K1.WT.1</td><td>0.62</td></tr><tr><td>MAP3K1.WT</td><td>0.69</td></tr></table></div>	Treatment	Score	CURNTA.WT	0.77	HRAS.G12V	0.71	KRAS.G12V	0.48	MAP3K1.WT	0.62	MAP3K1.WT.1	0.62	MAP3K1.WT	0.69	<div>NA</div>	<div></div>	<div></div>	<div></div>	<div>Total number of assays tested in: 518. Active in the following assays:</div> <div><ul style="list-style-type: none"><li>• Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin (AID 2314)</li><li>• Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine Kinase 33 Activity (AID 2661)</li><li>• Luminescence Cell-Free Homogenous Dose Retest to Identify Inhibitors of Serine/Threonine Kinase 33 Activity (AID 2821)</li><li>• Phenotypic HTS multiplex for antifungal efflux pump inhibitors (AID 485275)</li><li>• HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02.Inhibitor.SinglePoint.HTS (AID 485317)</li><li>• Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT) (AID 488975)</li><li>• Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01.Inhibitor.SinglePoint.HTS.Activity (AID 504441)</li><li>• MLPCN Dyrk1A Kinase Measured in Biochemical System Using Plate Reader - 2124-01.Inhibitor.Dose.CherryPick.Activity (AID 588945)</li><li>• HTS Assay for Peg3 Promoter Inhibitors (AID 588405)</li><li>• STK-33 Kinase Inhibition Measured in Biochemical System Using Plate Reader - 2052-02.Inhibitor.Dose.DryPowder.Activity.Set2 (AID 588480)</li><li>• uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay (AID 588493)</li><li>• STK-33 Kinase Inhibition Measured in Biochemical System Using Plate Reader - 2052-02.Inhibitor.Dose.DryPowder.Activity (AID 588632)</li><li>• Counter screen for activity against Aurora B, in dose Measured in Biochemical System Using Scintillation - 2052-06.Inhibitor.Dose.DryPowder.Activity.Set2 (AID 588756)</li><li>• uHTS identification of cystic fibrosis induced NFKb Inhibitors in a fluorescence assay (AID 588850)</li><li>• Single concentration confirmation of uHTS inhibitor hits from RPN11 in a Fluorescence Polarization assay (AID 602318)</li><li>• Single concentration validation of uHTS RPN11 inhibitor hits using a Thrombin Fluorescence Polarization assay (AID 602333)</li><li>• Single concentration confirmation of uHTS hits for Peg3 Promoter Inhibitors via a luciferase reporter assay (AID 602417)</li><li>• A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (AID 624296)</li><li>• A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (AID 624297)</li><li>• Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP - HeLa Cytotoxicity (AID 624300)</li><li>• Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP - Primary and Confirmatory Screens (AID 624330)</li><li>• Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP - Counter Screen Coupled Enzyme (AID 624351)</li><li>• HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-1 cells Measured in Cell-Based System Using Plate Reader - 7054-01.Inhibitor.SinglePoint.HTS.Activity (AID 652154)</li><li>• qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line (AID 686970)</li><li>• qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line (AID 686971)</li><li>• qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen (AID 743279)</li><li>• Confirmed inhibitors of Serine Threonine Kinase 33, STK33 (AID 743321)</li></ul></div>
Treatment	Score																					
CURNTA.WT	0.77																					
HRAS.G12V	0.71																					
KRAS.G12V	0.48																					
MAP3K1.WT	0.62																					
MAP3K1.WT.1	0.62																					
MAP3K1.WT	0.69																					
<div>BRD-K41273072-001-05-1</div> <div>ST50852444</div> <div>ZINC02857936</div> <div>MLS001124013</div> <div>AC1M3E68</div> <div>HMS2980L06</div> <div>ZINC2857936</div> <div>STK455432</div> <div>SMR000666470</div> <div>PubChem CID : 2211231</div>	<div></div>	<div>NA (in 1 replicates)</div>	<div><div>0.65 ± 0.12</div><table><tr><th>Treatment</th><th>Score</th></tr><tr><td>CURNTA.WT</td><td>0.78</td></tr><tr><td>HRAS.G12V</td><td>0.70</td></tr><tr><td>KRAS.G12V</td><td>0.44</td></tr><tr><td>MAP3K1.WT</td><td>0.62</td></tr><tr><td>MAP3K1.WT.1</td><td>0.65</td></tr><tr><td>MAP3K1.WT</td><td>0.71</td></tr></table></div>	Treatment	Score	CURNTA.WT	0.78	HRAS.G12V	0.70	KRAS.G12V	0.44	MAP3K1.WT	0.62	MAP3K1.WT.1	0.65	MAP3K1.WT	0.71	<div>NA</div>	<div></div>	<div></div>	<div></div>	<div>Total number of assays tested in: 492. Active in the following assays:</div> <div><ul style="list-style-type: none"><li>• uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase (AID 2524)</li><li>• Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels (AID 2642)</li></ul></div>
Treatment	Score																					
CURNTA.WT	0.78																					
HRAS.G12V	0.70																					
KRAS.G12V	0.44																					
MAP3K1.WT	0.62																					
MAP3K1.WT.1	0.65																					
MAP3K1.WT	0.71																					
<div>BRD-K15342451-001-05-7</div> <div>ZINC01422297</div> <div>AC1LT6KQ</div> <div>MLS000729012</div> <div>HMS2726N22</div> <div>ZINC1422297</div> <div>STK775737</div> <div>SMR000307290</div> <div>ST4103656</div> <div>PubChem CID : 1503254</div>	<div></div>	<div>NA (in 1 replicates)</div>	<div><div>-0.60 ± 0.05</div><table><tr><th>Treatment</th><th>Score</th></tr><tr><td>CURNTA.WT</td><td>0.58</td></tr><tr><td>HRAS.G12V</td><td>-0.39</td></tr><tr><td>KRAS.G12V</td><td>-0.38</td></tr><tr><td>MAP3K1.WT</td><td>-0.62</td></tr><tr><td>MAP3K1.WT.1</td><td>-0.53</td></tr><tr><td>MAP3K1.WT</td><td>-0.60</td></tr></table></div>	Treatment	Score	CURNTA.WT	0.58	HRAS.G12V	-0.39	KRAS.G12V	-0.38	MAP3K1.WT	-0.62	MAP3K1.WT.1	-0.53	MAP3K1.WT	-0.60	<div>NA</div>	<div></div>	<div></div>	<div></div>	<div>Total number of assays tested in: 626. Active in the following assays:</div> <div><ul style="list-style-type: none"><li>• MLPCN Alpha-Synuclein 5'UTR - 5'UTR binding - activators (AID 1814)</li><li>• Aqueous Solubility from MLSMR Stock Solutions (AID 1996)</li><li>• Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin (AID 2314)</li><li>• A qHTS for Small Molecule Inhibitors of Shiga Toxin (AID 2315)</li><li>• qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression (AID 624202)</li><li>• TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-mCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide (AID 686964)</li><li>• Counterscreen for inhibitors of 5-mCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide (AID 687016)</li></ul></div>
Treatment	Score																					
CURNTA.WT	0.58																					
HRAS.G12V	-0.39																					
KRAS.G12V	-0.38																					
MAP3K1.WT	-0.62																					
MAP3K1.WT.1	-0.53																					
MAP3K1.WT	-0.60																					





BRD-K47707616-001-06-3  
1134-36-7  
MLS000084764  
MLS000737887  
NSC 7950  
SMR000019110  
NSC7950  
ACMC-2099js  
AC1L243I  
AC1Q516N  
AC1Q516O  
ChEMBL574583  
BDBM37561  
CTK314347  
BB SC-8440  
HMS1473J22  
HMS2363K13  
KUC106663N  
ZINC154832  
KSC-22-7  
NSC-7950  
ANW-16646  
BBL008080  
SBB056916  
STK513465  
ZINC00154832  
CCG-103916  
PS-8495  
VZ26294  
IDI1 019538  
AJ-13396  
AK135459  
AN-48686  
BP-30020  
KB-19962  
LS-44455  
OR003129  
OR174385  
ZB005897  
DB-022223  
RT-001962  
3D49P06660  
A0397  
AM20120625  
BB 0246046  
FT-0614978  
R1875  
ST24041772  
ST45004729  
EN300-88962  
A803050  
I14-6050  
3B3-001248  
PubChem CID : 14562



NA (in 1 replicates)


-0.54 ± 0.07	
Treatment	Score
CHK2A.WT	-0.48
BRAS.GLV	-0.48
BRAS.GLV	-0.35
MAPK1.WT	-0.61
MAPK1.WT	-0.59
MAPK1.WT	-0.35

NA



- Total number of assays tested in: 835. Active in the following assays:
- NCI Yeast Anticancer Drug Screen. Data for the rad50 strain (AID 155)
  - NCI Yeast Anticancer Drug Screen. Data for the mec2-1 strain (AID 157)
  - NCI Yeast Anticancer Drug Screen. Data for the sgs1 mgt1 strain (AID 161)
  - NCI Yeast Anticancer Drug Screen. Data for the chn2 rad14 strain (AID 165)
  - NCI Yeast Anticancer Drug Screen. Data for the bub3 strain (AID 167)
  - NCI Yeast Anticancer Drug Screen. Data for the mlh1 rad18 strain (AID 175)
  - Aggregation and Clearance of Mutant Huntingtin Protein (AID 483)
  - qHTS Assay for Tau Filament Binding (AID 506)
  - qHTS Assay for Inhibitors of 15-lipoxygenase 2 (AID 881)
  - qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II) (AID 886)
  - qHTS Assay for Inhibitors of 15-lipoxygenase (AID 887)
  - qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4 (AID 893)
  - Primary Cell-based High Throughput Screening Assay for Inhibitors of Wee1 Degradation (AID 1321)
  - Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90) (AID 1789)
  - MLPCN Alpha-Synuclein 5'UTR - 5'UTR binding - activators (AID 1814)
  - qFRET-based primary biochemical high throughput screening assay to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP). (AID 1822)
  - Luminescence-based confirmation biochemical high throughput screening assay for inhibitors of the Heat Shock Protein 90 (HSP90) (AID 1846)
  - Luminescence-based dose response biochemical high throughput screening assay for inhibitors of the Heat Shock Protein 90 (HSP90) (AID 1913)
  - qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen (AID 2100)
  - Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin (AID 2314)
  - A qHTS for Small Molecule Inhibitors of Shiga Toxin (AID 2315)
  - HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02-Inhibitor.SinglePoint.HTS (AID 485317)
  - qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a (AID 504332)
  - qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1 (AID 504467)
  - In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01-Inhibitor.SinglePoint.HTS.Activity (AID 504582)
  - Primary qHTS for delayed death inhibitors of the malarial parasite plasmod, 96 hour incubation (AID 504834)
  - qHTS profiling assay for firefly luciferase inhibitor/activator using purified enzyme and Km concentrations of substrates (counterscreen for miR-21 project) (AID 588342)
  - Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators (AID 624464)
  - qHTS Assay for Activators of ClpP (AID 651965)
  - qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen (AID 720504)




BRD-K22606571-001-05-1  
ZINC02277811  
AC1LCZ96  
MLS000079219  
HMS2426D20  
ZINC2277811  
STK759250  
SMR000035371  
ST049350  
PubChem CID : 658691



NA (in 1 replicates)


-0.53 ± 0.08	
Treatment	Score
CHK2A.WT	-0.62
BRAS.GLV	-0.36
BRAS.GLV	-0.39
MAPK1.WT	-0.35
MAPK1.WT	-0.48
MAPK1.WT	-0.37

NA



- Total number of assays tested in: 760. Active in the following assays:
- Human A549 Lung Tumor Cell Growth Inhibition Assay (AID 371)
  - CYP2C9 Assay (AID 777)
  - qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway (AID 915)
  - Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao. (AID 1441)
  - Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions. (AID 1504)
  - qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP) (AID 1688)
  - Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT) (AID 488975)
  - Confirmatory screen for compounds that inhibit the Choline Transporter (CHT) (AID 493221)
  - Nr2 qHTS screen for inhibitors (AID 504444)
  - Dose responses of compounds that inhibit the Choline Transporter (CHT) - 5 point CRC (AID 504840)
  - Dose responses of compounds that inhibit the Choline Transporter (CHT) - 10 point CRC (AID 588401)
  - A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression (AID 624263)
  - qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS (AID 624288)
  - Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease (AID 624483)
  - qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT (AID 686978)
  - qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT (AID 686979)
  - Confirmed inhibitors of the Choline Transporter (CHT) (AID 1053196)




BRD-K84625203-001-01-1  
PubChem CID : 54646078



NA (in 1 replicates)


-0.53 ± 0.05	
Treatment	Score
CHK2A.WT	-0.47
BRAS.GLV	-0.48
BRAS.GLV	-0.44
MAPK1.WT	-0.35
MAPK1.WT	-0.59
MAPK1.WT	-0.53

0.576 ± 0.382	
Treatment	Score
CHK2A.WT	0.480
BRAS.GLV	0.269
BRAS.GLV	0.177
MAPK1.WT	0.592
MAPK1.WT	0.608
MAPK1.WT	0.312



Total number of assays tested in: 40.




BRD-K90734091-001-01-8  
PubChem CID : 44489743



0.76 (in 4 replicates)





















-0.53 ± 0.08	
Treatment	Score
CHK2A.WT	-0.45
BRAS.GLV	-0.44
BRAS.GLV	-0.30
MAPK1.WT	-0.59
MAPK1.WT	-0.36
MAPK1.WT	-0.68

NA



Total number of assays tested in: 52.



<div>BRD-K15827540-001-05-0</div> <div>T5250099</div> <div>AC1M2QX1</div> <div>MLS001010624</div> <div>HMS1774C11</div> <div>HMS2718E22</div> <div>ZINC12531006</div> <div>SMR000352827</div> <div>PubChem CID : 2123280</div>		NA (in 1 replicates)	<div>-0.53 ± 0.06</div> <table><tr><th>Treatment</th><th>Score</th></tr><tr><td>CHK2A.WT</td><td>-0.45</td></tr><tr><td>BRAS.G2V</td><td>-0.49</td></tr><tr><td>BRAS.G2P</td><td>-0.61</td></tr><tr><td>MAPK1.WT</td><td>-0.56</td></tr><tr><td>MAPK1.WT.1</td><td>-0.61</td></tr><tr><td>MAPK1.WT</td><td>-0.55</td></tr></table>	Treatment	Score	CHK2A.WT	-0.45	BRAS.G2V	-0.49	BRAS.G2P	-0.61	MAPK1.WT	-0.56	MAPK1.WT.1	-0.61	MAPK1.WT	-0.55	NA				<div>Total number of assays tested in: 643. Active in the following assays:</div> <ul style="list-style-type: none"><li>Primary cell-based high throughput screening assay to measure STAT3 inhibition (AID 862)</li><li>Counter Screen for Luciferase-based Primary Inhibition Assays (AID 1006)</li><li>qHTS Assay for Enhancers of SMN2 Splice Variant Expression (AID 1458)</li><li>qHTS Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase (LmPK) (AID 1721)</li><li>Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90) (AID 1789)</li><li>qHTS for inhibitors of ROR gamma transcriptional activity (AID 2551)</li><li>qHTS Assay for Rab9 Promoter Activators (AID 485297)</li><li>qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1 (AID 504466)</li><li>qHTS for Inhibitors of binding or entry into cells for Lassa Virus (AID 540256)</li><li>qHTS profiling assay for firefly luciferase inhibitor/activator using purified enzyme and Km concentrations of substrates (counterscreen for miR-21 project) (AID 588342)</li><li>Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1 (AID 652010)</li><li>qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen (AID 720504)</li></ul>														
Treatment	Score																																			
CHK2A.WT	-0.45																																			
BRAS.G2V	-0.49																																			
BRAS.G2P	-0.61																																			
MAPK1.WT	-0.56																																			
MAPK1.WT.1	-0.61																																			
MAPK1.WT	-0.55																																			
<div>BRD-K83390709-001-01-2</div> <div>PubChem CID : 54657529</div>		0.59 (in 4 replicates)	<div>-0.52 ± 0.03</div> <table><tr><th>Treatment</th><th>Score</th></tr><tr><td>CHK2A.WT</td><td>-0.36</td></tr><tr><td>BRAS.G2V</td><td>-0.32</td></tr><tr><td>BRAS.G2V</td><td>-0.32</td></tr><tr><td>MAPK1.WT</td><td>-0.38</td></tr><tr><td>MAPK1.WT.1</td><td>-0.32</td></tr><tr><td>MAPK1.WT</td><td>-0.34</td></tr></table>	Treatment	Score	CHK2A.WT	-0.36	BRAS.G2V	-0.32	BRAS.G2V	-0.32	MAPK1.WT	-0.38	MAPK1.WT.1	-0.32	MAPK1.WT	-0.34	<div>0.287 ± 0.051</div> <table><tr><th>Treatment</th><th>Score</th></tr><tr><td>CHK2A.WT</td><td>0.362</td></tr><tr><td>BRAS.G2V</td><td>0.282</td></tr><tr><td>BRAS.G2V</td><td>0.306</td></tr><tr><td>MAPK1.WT</td><td>0.222</td></tr><tr><td>MAPK1.WT.1</td><td>0.297</td></tr><tr><td>MAPK1.WT</td><td>0.312</td></tr></table>	Treatment	Score	CHK2A.WT	0.362	BRAS.G2V	0.282	BRAS.G2V	0.306	MAPK1.WT	0.222	MAPK1.WT.1	0.297	MAPK1.WT	0.312				<div>Total number of assays tested in: 39.</div>
Treatment	Score																																			
CHK2A.WT	-0.36																																			
BRAS.G2V	-0.32																																			
BRAS.G2V	-0.32																																			
MAPK1.WT	-0.38																																			
MAPK1.WT.1	-0.32																																			
MAPK1.WT	-0.34																																			
Treatment	Score																																			
CHK2A.WT	0.362																																			
BRAS.G2V	0.282																																			
BRAS.G2V	0.306																																			
MAPK1.WT	0.222																																			
MAPK1.WT.1	0.297																																			
MAPK1.WT	0.312																																			
<div>BRD-K60430317-001-01-7</div> <div>PubChem CID : 44490267</div>		0.67 (in 4 replicates)	<div>-0.52 ± 0.09</div> <table><tr><th>Treatment</th><th>Score</th></tr><tr><td>CHK2A.WT</td><td>-0.60</td></tr><tr><td>BRAS.G2V</td><td>-0.32</td></tr><tr><td>BRAS.G2V</td><td>-0.39</td></tr><tr><td>MAPK1.WT</td><td>-0.38</td></tr><tr><td>MAPK1.WT.1</td><td>-0.44</td></tr><tr><td>MAPK1.WT</td><td>-0.50</td></tr></table>	Treatment	Score	CHK2A.WT	-0.60	BRAS.G2V	-0.32	BRAS.G2V	-0.39	MAPK1.WT	-0.38	MAPK1.WT.1	-0.44	MAPK1.WT	-0.50	<div>0.266 ± 0.221</div> <table><tr><th>Treatment</th><th>Score</th></tr><tr><td>CHK2A.WT</td><td>0.257</td></tr><tr><td>BRAS.G2V</td><td>0.242</td></tr><tr><td>BRAS.G2V</td><td>0.306</td></tr><tr><td>MAPK1.WT</td><td>0.180</td></tr><tr><td>MAPK1.WT.1</td><td>0.160</td></tr><tr><td>MAPK1.WT</td><td>0.058</td></tr></table>	Treatment	Score	CHK2A.WT	0.257	BRAS.G2V	0.242	BRAS.G2V	0.306	MAPK1.WT	0.180	MAPK1.WT.1	0.160	MAPK1.WT	0.058				<div>Total number of assays tested in: 54.</div>
Treatment	Score																																			
CHK2A.WT	-0.60																																			
BRAS.G2V	-0.32																																			
BRAS.G2V	-0.39																																			
MAPK1.WT	-0.38																																			
MAPK1.WT.1	-0.44																																			
MAPK1.WT	-0.50																																			
Treatment	Score																																			
CHK2A.WT	0.257																																			
BRAS.G2V	0.242																																			
BRAS.G2V	0.306																																			
MAPK1.WT	0.180																																			
MAPK1.WT.1	0.160																																			
MAPK1.WT	0.058																																			
<div>BRD-K73732735-001-05-6</div> <div>MLS000040829</div> <div>AC1LDCIY</div> <div>HMS1603D16</div> <div>HMS2167K06</div> <div>HMS3317D19</div> <div>ZINC1238777</div> <div>STL057406</div> <div>ZINC01238777</div> <div>SMR000045729</div> <div>PubChem CID : 664852</div>		NA (in 1 replicates)	<div>-0.52 ± 0.07</div> <table><tr><th>Treatment</th><th>Score</th></tr><tr><td>CHK2A.WT</td><td>-0.36</td></tr><tr><td>BRAS.G2V</td><td>-0.34</td></tr><tr><td>BRAS.G2V</td><td>-0.37</td></tr><tr><td>MAPK1.WT</td><td>-0.37</td></tr><tr><td>MAPK1.WT.1</td><td>-0.32</td></tr><tr><td>MAPK1.WT</td><td>-0.36</td></tr></table>	Treatment	Score	CHK2A.WT	-0.36	BRAS.G2V	-0.34	BRAS.G2V	-0.37	MAPK1.WT	-0.37	MAPK1.WT.1	-0.32	MAPK1.WT	-0.36	NA				<div>Total number of assays tested in: 776. Active in the following assays:</div> <ul style="list-style-type: none"><li>qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region (AID 589)</li><li>qHTS Assay for Spectroscopic Profiling in A350 Spectral Region (AID 590)</li><li>Profiling the NIH Molecular Libraries Small Molecule Repository: Autofluorescence at 339/460 nm (AID 709)</li><li>qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4 (AID 893)</li><li>Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex (AID 2216)</li><li>qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a (AID 504332)</li><li>A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (AID 624296)</li><li>A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (AID 624297)</li><li>qHTS Assay for Inhibitors of Hepatitis C Virus (HCV) (AID 651820)</li></ul>														
Treatment	Score																																			
CHK2A.WT	-0.36																																			
BRAS.G2V	-0.34																																			
BRAS.G2V	-0.37																																			
MAPK1.WT	-0.37																																			
MAPK1.WT.1	-0.32																																			
MAPK1.WT	-0.36																																			
<div>BRD-A04171102-003-05-4</div> <div>SMR000008890</div> <div>MLS000029546</div> <div>AC1O7EQU</div> <div>MLS002535860</div> <div>PubChem CID : 6602543</div>		NA (in 1 replicates)	<div>-0.52 ± 0.06</div> <table><tr><th>Treatment</th><th>Score</th></tr><tr><td>CHK2A.WT</td><td>-0.61</td></tr><tr><td>BRAS.G2V</td><td>-0.50</td></tr><tr><td>BRAS.G2V</td><td>-0.53</td></tr><tr><td>MAPK1.WT</td><td>-0.50</td></tr><tr><td>MAPK1.WT.1</td><td>-0.48</td></tr><tr><td>MAPK1.WT</td><td>-0.53</td></tr></table>	Treatment	Score	CHK2A.WT	-0.61	BRAS.G2V	-0.50	BRAS.G2V	-0.53	MAPK1.WT	-0.50	MAPK1.WT.1	-0.48	MAPK1.WT	-0.53	NA				<div>Total number of assays tested in: 761. Active in the following assays:</div> <ul style="list-style-type: none"><li>qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase) (AID 1490)</li><li>qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a (AID 504332)</li><li>qHTS Assay for Inhibitors of JMJD2A-Tudor Domain (AID 504339)</li></ul>														
Treatment	Score																																			
CHK2A.WT	-0.61																																			
BRAS.G2V	-0.50																																			
BRAS.G2V	-0.53																																			
MAPK1.WT	-0.50																																			
MAPK1.WT.1	-0.48																																			
MAPK1.WT	-0.53																																			